GLUE ▲ +1.2% - Monte Rosa Therapeutics, Inc. $GLUE - Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Monte Rosa Therapeutics announced a clinical milestone with the initiation of a Phase 2 study for its VAV1-directed molecular glue degrader MRT-6160, prompting a 1.2% gain in $GLUE shares. The advancement to Phase 2 represents a key progression in the company's pipeline and demonstrates progress toward potential therapeutic applications for the compound. 08-SEP-2026 07:00 AM ET